15360676961
首页 > 新闻中心 > 研发生产氟比洛芬CAS: 51543-40-9;5104-49-4原料供应发货南京工厂直销现货直销
新闻中心
研发生产氟比洛芬CAS: 51543-40-9;5104-49-4原料供应发货南京工厂直销现货直销
发布时间:2023-10-18        浏览次数:15        返回列表
研发生产氟比洛芬CAS: 51543-40-9;5104-49-4原料供应发货南京工厂直销现货直销
中文名氟比洛芬
英文名(2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
别名氟比洛芬
R-氟比洛
(R)-氟比洛芬
R(-)氟比洛芬
(R)-2-氟比洛芬
氟比洛芬 EP标准品
(R)-(-)-2-氟-Α-甲基-4-联苯乙酸
(R)-(-)-2-氟-alpha-甲基-4-联苯乙酸
(R)-(-)-2-氟-ALPHA-甲基-4-联苯乙酸
英文别名Flurizan
MPC 7869
Flurbiprofen
(R)-2-Flurbiprofen
(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid
(2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
(R)-2-Fluoro-α-methyl-1,1'-biphenyl-4-acetic acid
(R)-α-Methyl-2-fluoro-1,1'-biphenyl-4-acetic acid
(R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
1,4-bis(heptafluoropropan-2-yl)benzene
[1,1'-Biphenyl]-4-aceticacid, 2-fluoro-a-Methyl-,(aR)-
(R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid (Flurbiprofe
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (alphaR)-
CAS51543-40-9
5104-49-4
EINECS
化学式C15H13FO2
分子量244.26
InChIInChI=1/C12H4F14/c13-7(9(15,16)17,10(18,19)20)5-1-2-6(4-3-5)8(14,11(21,22)23)12(24,25)26/h1-4H
密度1.199±0.06 g/cm3(Predicted)
熔点110-113°C(lit.)
沸点376.2±30.0 °C(Predicted)
闪点57.7°C
蒸汽压2.84mmHg at 25°C
溶解度Soluble  in  DMSO  (50  mg/ml),  methanol  (50  mg/ml),  ethanol  (~100  mg/ml),  DMF  (~100  mg/ml)
折射率1.34
酸度系数4.14±0.10(Predicted)
存储条件Room Temprature
外观Crystalline Powder
颜色White to off-white
MDL号MFCD00079303
体外研究Tarenflurbil ((R)-Flurbiprofen) can significantly reduce Aβ secretion, but at the same time, increases the level of intracellular Aβ. The binding between [ 3 H]9-cis-RA and RXRα is competitively inhibited by both unlabeled (R)-Flurbiprofen and 9-cis-RA. (R)-Flurbiprofen can interfere with the interaction between RXRα and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases Tarenflurbil ((R)-Flurbiprofen)’s reduction of Aβ secretion. Tarenflurbil ((R)-Flurbiprofen) treatment significantly increases the levels of intracellular Aβ species. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), Tarenflurbil ((R)-Flurbiprofen) affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing.
体内研究Effects of the early and late onset of treatment with Tarenflurbil ((R)-Flurbiprofen) are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapsing-remitting (RR)-EAE. Tarenflurbil ((R)-Flurbiprofen) completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of Tarenflurbil ((R)-Flurbiprofen) are comparable to those of Fingolimod (FTY720, 0.5 mg/kg/day), which is used as the positive control. Tarenflurbil ((R)-Flurbiprofen) also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day).


核心提示:医药中间体
刚发布的文章
联系方式
  • 地址:江苏省南京市雨花台区安德门大街57号
  • 电话:15360676961
  • 手机:15360676961
  • 传真:南京辰瑞晟生物医药科技有限公司
  • 联系人:诸璐
新闻分类
最新发布
企业新闻